title: Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment?
abstract: Historically, there were few effective and durable treatments for metastatic melanoma. Recently, mutation based targeted therapies have revolutionized treatment and outcomes for patients with metastatic melanoma. Specifically, inhibitors aimed at BRAF, NRAS, and C-KIT mutations are now commonly used in treatment for patients harboring the specific mutations. Areas covered: A brief review of current BRAF, NRAS, and C-KIT inhibitors provides background for a thorough review of newly developed agents namely binimetinib, a MEK inhibitor, encorafenib a BRAF inhibitor, and masitinib which inhibits C-KIT. Expert opinion: While the 3 novel agents reviewed here have potential for use in melanoma, optimal utilization will occur once a more personalized approach incorporating genomic, proteomic, and immunologic data guides therapeutic decisions.
authors.affiliation: a Department of Surgery , Duke University , Durham , NC , USA.
authors.forename: Megan C
authors.initials: MC
authors.lastname: Turner
authors.affiliation: b Department of Surgery , Ohio State University , Columbus , OH , USA.
authors.forename: Kara
authors.initials: K
authors.lastname: Rossfeld
authors.affiliation: c Department of Medicine , Duke University , Durham , NC , USA.
authors.forename: April K S
authors.initials: AK
authors.lastname: Salama
authors.affiliation: d Department of Surgery , University of Texas Medical Branch at Galveston , Galveston , TX , USA.
authors.forename: Douglas
authors.initials: D
authors.lastname: Tyler
authors.affiliation: b Department of Surgery , Ohio State University , Columbus , OH , USA.
authors.forename: Georgia
authors.initials: G
authors.lastname: Beasley
mesh_terms: D001549:Benzamides; D001562:Benzimidazoles / Q000627:therapeutic use; D002219:Carbamates / Q000627:therapeutic use; D006801:Humans; D008545:Melanoma / Q000188:drug therapy*; D009154:Mutation; D010880:Piperidines; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D040901:Proteomics; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics; D011725:Pyridines; D012878:Skin Neoplasms / Q000188:drug therapy*; D013449:Sulfonamides / Q000627:therapeutic use; D013844:Thiazoles / Q000627:therapeutic use
chemical_list: D001549:Benzamides; D001562:Benzimidazoles; D002219:Carbamates; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D013449:Sulfonamides; D013844:Thiazoles; C581313:binimetinib; C000601108:encorafenib; D019009:Proto-Oncogene Proteins c-kit; D048493:Proto-Oncogene Proteins B-raf; C526575:masitinib
keywords: BRAF; MEK; Melanoma; c-kit; targeted therapy